Literature DB >> 229343

Cyclic adenosine monophosphate excretion in urine of patients and carriers of congenital nephrogenic diabetes insipidus.

W S Uttley, B Atkinson, A Adams, D Shirling.   

Abstract

Urinary excretion of cyclic adenosine monophosphate (cAMP) is assessed in response to pitressin stimulation in three patients with nephrogenic diabetes insipidus, four carriers and seven controls. There is no significant difference in cAMP excretion between these groups when corrected for surface area, nor is there any significant increase in excretion after pitressin stimulation. There is very close correlation between urinary cAMP and both urinary concentration and urinary creatinine excretion. Urinary cAMP after pitressin stimulation does not discriminate between carriers of nephrogenic diabetes insipidus and control subjects.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 229343     DOI: 10.1007/bf01801849

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  12 in total

1.  The carrier state in nephrogenic diabetes insipidus.

Authors:  C CARTER; M SIMPKISS
Journal:  Lancet       Date:  1956-11-24       Impact factor: 79.321

2.  Demonstration of a defect in the formation of adenosine 3',5'-monophosphate in vasopressin-resistant diabetes insipidus.

Authors:  N H Bell; C M Clark; S Avery; T Sinha; C W Trygstad; D O Allen
Journal:  Pediatr Res       Date:  1974-04       Impact factor: 3.756

3.  Saturation assay for cyclic AMP using endogenous binding protein.

Authors:  B L Brown; R P Ekins; J D Albano
Journal:  Adv Cyclic Nucleotide Res       Date:  1972

4.  Nephrogenic diabetes insipidus. Effects of 3,5, cyclic-adenosine monophosphate.

Authors:  N F Jones; M A Barraclough; N Barnes; D G Cottom
Journal:  Arch Dis Child       Date:  1972-10       Impact factor: 3.791

5.  Deficient renal cyclic adenosine 3'-5' monophosphate production in nephrogenic diabetes insipidus.

Authors:  M P Fichman; G Brooker
Journal:  J Clin Endocrinol Metab       Date:  1972-07       Impact factor: 5.958

6.  Urinary cyclic adenosine monophosphate excretion in diabetes insipidus of childhood. Effect of vasopressin and chlorpropamide.

Authors:  K Raij; J Perheentupa; M Härkönen
Journal:  Scand J Clin Lab Invest       Date:  1974-10       Impact factor: 1.713

7.  Failure to detect the carrier in congenital nephrogenic diabetes insipidus.

Authors:  W S Uttley; D Thistlethwaite
Journal:  Arch Dis Child       Date:  1972-02       Impact factor: 3.791

8.  Renal adenyl cyclase: anatomically separate sites for parathyroid hormone and vasopressin.

Authors:  L R Chase; G D Aurbach
Journal:  Science       Date:  1968-02-02       Impact factor: 47.728

9.  Pseudohypoparathyroidism: defective excretion of 3',5'-AMP in response to parathyroid hormone.

Authors:  L R Chase; G L Melson; G D Aurbach
Journal:  J Clin Invest       Date:  1969-10       Impact factor: 14.808

10.  Kinetic parameters and renal clearances of plasma adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in man.

Authors:  A E Broadus; N I Kaminsky; J G Hardman; E W Sutherland; G W Liddle
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.